Wells Fargo & Company Reviva Pharmaceuticals Holdings, Inc. Transaction History

Wells Fargo & Company

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.76 - $5.52 $99 - $198	36 Added 25.9%	175 $0
Q4 2023 Feb 09, 2024	SELL	$3.56 - $6.04 $17,775 - $30,157	-4,993 Reduced 97.29%	139 $0
Q3 2023 Nov 13, 2023	BUY	$3.91 - $5.9 $66 - $100	17 Added 0.33%	5,132 $25,000
Q2 2023 Aug 15, 2023	BUY	$4.42 - $8.55 $22,122 - $42,792	5,005 Added 4550.0%	5,115 $29,000
Q1 2023 May 12, 2023	BUY	$3.79 - $4.87 $3 - $4	1 Added 0.92%	110 $0
Q4 2022 Feb 13, 2023	BUY	$1.68 - $5.99 $65 - $233	39 Added 55.71%	109 $0
Q3 2022 Nov 14, 2022	SELL	$0.14 - $2.66 $0 - $2	-1 Reduced 1.41%	70 $0
Q2 2022 Aug 12, 2022	SELL	$1.03 - $2.47 $31 - $76	-31 Reduced 30.39%	71 $0
Q1 2022 May 16, 2022	BUY	$1.61 - $3.01 $8 - $15	5 Added 5.15%	102 $0
Q4 2021 Feb 14, 2022	BUY	$2.7 - $4.23 $175 - $274	65 Added 203.13%	97 $0
Q3 2021 Nov 15, 2021	SELL	$3.29 - $4.79 $6 - $9	-2 Reduced 5.88%	32 $0
Q1 2021 May 13, 2021	BUY	$5.4 - $9.49 $183 - $322	34 New	34 $0

9.97M

133K

43.9K

Ticker RVPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,442,900
Market Cap $26M
Description
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is RP506...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.